evipedia.ai
← Back

Zinc-L-Carnosine for Health & Longevity

Evidence Review created on 09/12/2026 using AI4L / Opus 5

Also known as: Polaprezinc, Zinc Carnosine, Zinc-Carnosine Complex, Z-103, PepZin GI, Promac, N-(3-aminopropionyl)-L-histidinato zinc

Motivation

Zinc-L-carnosine (polaprezinc) is a manufactured complex that links the mineral zinc to carnosine, a small compound built from two amino acids and found naturally in meat and fish. It barely dissolves in water, so instead of being absorbed quickly like ordinary zinc salts it travels through the digestive tract as fine particles and clings to damaged tissue, releasing zinc where the lining is injured. Japan approved it as a prescription medication for stomach ulcers in 1994; elsewhere it is sold as a dietary supplement.

Attention outside Japan widened once researchers asked whether that same local repair effect might protect the gut lining against ordinary stressors such as anti-inflammatory medication and hard endurance exercise, and whether it might ease the mouth and throat injury caused by cancer treatment. It is also used to raise low zinc levels.

This review examines what the evidence shows about zinc-L-carnosine’s effects on the digestive lining, on zinc status and on taste, together with the risks of sustained zinc intake, the dosing regimens that have been studied, and the quality and funding of the underlying research.

Benefits - Risks - Protocol - Conclusion

A short list of high-level overviews of zinc-L-carnosine drawn from expert platforms and non-systematic scientific literature.

Of the six priority platforms, only Life Extension publishes substantial dedicated content on zinc-L-carnosine. Peter Attia, Andrew Huberman, Chris Kresser, FoundMyFitness and Lifespan.io returned no relevant results on web or on-site search — the compound is a Japanese gastroenterology medication with little presence in English-language longevity writing. The remaining slots were filled with narrative and literature reviews rather than marginal material.

Grokipedia

  • Zinc L-carnosine

    A broad encyclopaedic entry covering chemistry, the Japanese regulatory history, mechanism and the main clinical indications, useful as a quick orientation before reading the primary literature.

Examine

No Examine article exists for zinc-L-carnosine. Examine.com covers the compound only through individual research-feed study summaries and its general Zinc page, with no dedicated entry for zinc-L-carnosine or polaprezinc. Zinc-L-carnosine is a prescription medication in Japan, and Examine’s catalogue is built around supplement ingredients rather than prescription medications, which plausibly explains the absence.

ConsumerLab

Systematic Reviews

The systematic reviews and meta-analyses that bear most directly on zinc-L-carnosine’s claimed benefits and on its principal risk.

Mechanism of Action

Zinc-L-carnosine is a chelate, a lattice in which zinc ions are locked between molecules of the dipeptide L-carnosine. The pairing is deliberate: carnosine keeps zinc insoluble at neutral pH, so the compound is not absorbed promptly the way zinc sulphate is but disperses through the stomach as fine particles. Damaged tissue binds the complex more avidly than healthy tissue, and a chemical exchange releases zinc preferentially at ulcerated sites — a targeting effect neither component achieves alone. The pharmacological consequence of pairing them is a high local zinc concentration with a low systemic zinc load.

Locally released zinc scavenges free radicals and switches on protective genes. It induces heme oxygenase-1 (HO-1, an enzyme that dismantles heme and limits oxidative injury) through the Nrf2 pathway (a cellular switch that turns on antioxidant genes), raises heat shock protein 70 (HSP70, a chaperone that stabilises proteins under stress), and suppresses NF-κB (a master switch for inflammatory genes) and the inflammatory signal interleukin-8. It also stimulates epithelial cells to migrate and divide, partly through insulin-like growth factor 1 (IGF-1, a growth signal), and stabilises tight junctions by increasing occludin.

A competing reading holds that the complex is simply a zinc-delivery vehicle: carnosine alone matched it in one pressure-ulcer trial, suggesting the dipeptide contributes independently. The compound is not a cytochrome P450 (CYP, the liver’s main drug-metabolising enzyme family) substrate; carnosine reaching the blood is cleaved within minutes by serum carnosinase, while absorbed zinc follows normal handling with slow whole-body turnover and predominantly faecal elimination.

Historical Context & Evolution

Zinc-L-carnosine was developed in Japan during the 1980s by Hamari Chemicals and Zeria Pharmaceutical under the code Z-103, with a single original purpose: healing peptic ulcers. The design brief was explicitly local. Zinc salts had shown gastroprotective effects, but systemic zinc dosing carried mineral-balance problems, so chemists sought a form that would sit on the ulcer rather than enter the bloodstream. Approval followed in Japan in 1994 under the brand name Promac, and the compound became a routine anti-ulcer and gastritis medication there.

Two developments pulled it beyond gastroenterology. First, Japanese oncology teams observed that a medication that repairs the stomach lining might also repair the mouth and oesophagus, and began testing it for the mucosal injury caused by radiotherapy and chemotherapy. Second, a 2007 British study showed the compound blunted the rise in intestinal permeability caused by an anti-inflammatory drug in healthy volunteers — reframing it as something a healthy person might take, not only a patient with an ulcer. Sales as a dietary supplement outside Japan followed, largely under the PepZin GI trademark.

The scientific picture has not settled into a consensus so much as into an asymmetry. Efficacy trials cluster in Japan, Korea and China and are frequently small; Western regulators have not evaluated the indications at all, and the European Food Safety Authority declined in 2022 to conclude that the supplement form is safe, citing incomplete particle characterisation rather than any observed harm. Neither position has been overturned by the other.

Expected Benefits

High 🟩 🟩 🟩

Faster Healing of Gastric and Post-Procedural Ulcers

The complex adheres to ulcerated gastric tissue and releases zinc at the injury site, speeding regrowth of the surface layer. Japan licensed it in 1994 on endoscopically confirmed healing data. A 210-patient RCT in ulcers created by endoscopic submucosal dissection (ESD — removal of an early gastric tumour through an endoscope) found it non-inferior to rebamipide when each was added to acid suppression, and a network meta-analysis of 20 RCTs placed protectant-plus-acid-suppression combinations above acid suppression alone. Much of the registration evidence was manufacturer-funded.

Magnitude: 90.3% ulcer healing at four weeks with 150 mg/day plus pantoprazole, against 91.4% for rebamipide plus pantoprazole, by intention-to-treat analysis (every randomised patient counted, whatever they actually took); p=0.523, meaning the difference is well within chance.

Higher Helicobacter pylori Eradication When Added to Antibiotics

Helicobacter pylori is the bacterium behind most stomach ulcers and a major driver of gastric cancer, and rising antibiotic resistance has eroded cure rates. Zinc-L-carnosine is not itself an antibiotic; it appears to work by damping the bacterium-driven inflammation and stabilising the mucus layer, letting antibiotics act. A meta-analysis of three RCTs in 396 patients found a consistent gain when it was added to standard triple therapy, with no increase in side effects. The evidence base is small and regionally concentrated, and the authors themselves call it scarce.

Magnitude: Odds ratio (how much more likely the outcome is with treatment) 2.01, with a 95% confidence interval (the range the true value most probably falls in) of 1.27–3.21 for eradication by intention-to-treat, and 2.65 (1.55–4.54) among those who completed treatment as planned.

Restoration of Serum Zinc in Zinc Deficiency

Serum zinc is the standard clinical measure of zinc status, and low zinc is common in older adults, in chronic kidney disease and in liver disease. An individual-patient meta-analysis of four placebo-controlled RCTs confirmed a dose-dependent rise, and a one-year RCT in 75 haemodialysis patients showed that the effect is sustained. The meta-analysis was conducted and authored by the manufacturer, Zeria Pharmaceutical, using its own trial database — a direct financial interest in the result. Doses of 300 mg/day suited baselines below 70 µg/dL and 150 mg/day suited higher baselines.

Magnitude: Mean rise of 9.08 µg/dL over placebo (95% confidence interval 5.46–12.70) across pooled doses, with a significant dose-response relationship (p<0.001).

Medium 🟩 🟩

Protection of Intestinal Barrier Integrity Under Chemical and Thermal Stress

A leaky intestinal barrier lets bacterial fragments cross into the circulation, and both anti-inflammatory medication and hard exercise reliably open it. Two small double-blind crossover RCTs from one research group — ten volunteers given indomethacin and eight athletes exercising to a 2 °C core-temperature rise — found the compound largely abolished the induced rise in permeability, with tight-junction stabilisation as the proposed mechanism. The endpoint is a urinary sugar-excretion ratio, not a symptom or clinical event, and no trial shows that preventing this shift changes how anyone feels.

Magnitude: Indomethacin tripled the lactulose:rhamnose ratio (0.35 to 0.88) with no significant rise when the compound was co-administered; exercise-induced rise was cut by 70% after 14 days.

Improvement of Taste Disturbance

Loss or distortion of taste follows zinc depletion, chemotherapy, and kidney disease, and it matters because it drives appetite loss and weight loss. A meta-analysis of 12 RCTs in 938 subjects found zinc supplementation improved unexplained and deficiency-related taste disorders, with polaprezinc among the salts tested but not analysed separately; a cohort of 634 patients on chemotherapy found it shortened episodes of taste disturbance, though not in pancreatic cancer, not with gemcitabine, and not in those aged 65 and over. The compound-specific evidence is therefore indirect.

Magnitude: Risk ratio (relative chance of the outcome) 1.38, 95% confidence interval 1.16–1.64, for improvement with zinc supplementation overall; no polaprezinc-specific pooled figure has been published.

Improvement of Hepatic Encephalopathy in Cirrhosis

Hepatic encephalopathy (confusion and impaired thinking caused by advanced liver disease) is driven partly by ammonia the failing liver cannot clear, and the enzymes that clear it need zinc, which cirrhosis depletes. A randomised trial in 79 patients with cirrhosis added 225 mg/day to standard care for six months and found lower encephalopathy grade, lower blood ammonia, better Child-Pugh scores (a standard liver-severity measure) and better cognitive test results. The comparison arm continued standard care unblinded, and the finding stands on one trial.

Magnitude: Encephalopathy grade, blood ammonia, Child-Pugh score and cognitive test results all moved in favour of the compound over six months (p=0.03, 0.01, 0.04 and 0.02 respectively); the trial reports statistical significance without an effect size for any of them.

Low 🟩

Reduced Severity of Chemoradiotherapy-Induced Oral Mucositis ⚠️ Conflicted

A 2026 meta-analysis of eight studies found fewer severe mouth ulcers under a fixed-effect model (assuming one shared true effect) but not under random effects (allowing between-study variation). Certainty was low and six of eight studies were non-randomised. The net reading is a plausible but unproven benefit.

Magnitude: Odds ratio 0.48 (95% confidence interval 0.32–0.72) for grade 3 or worse mucositis under the fixed-effect model, falling to 0.44 (0.18–1.06) under random effects.

Adjunctive Mucosal Healing in Ulcerative Colitis

A single investigator-blinded trial in 28 patients added a 150 mg enema to standard induction therapy for one week and saw better endoscopic and clinical scores. The route was rectal, not oral, so the finding does not transfer to capsules, and the comparison group was untreated rather than placebo-controlled.

Magnitude: Clinical response or remission in 71% of the treated group versus 10% of controls at day 8.

Accelerated Pressure Ulcer Healing

A non-randomised controlled trial in 42 long-term care patients found faster wound-score improvement over four weeks. Carnosine alone performed just as well as the zinc complex, which argues the zinc component is not doing the work here. Allocation was by order of recruitment, not chance.

Magnitude: Mean weekly improvement in the Pressure Ulcer Scale for Healing score of 1.8 with the complex and 1.6 with carnosine alone, against 0.8 untreated.

Relief of Reflux and Regurgitation Symptoms

The compound is marketed across Europe for reflux, and a two-centre randomised trial in 60 infants matched thickened formula on symptom scores while cutting regurgitation frequency more. The population is infants, not adults, and the adult heartburn and reflux-maintenance trials have reported no results.

Magnitude: Both arms improved significantly on a validated infant reflux symptom score at eight weeks, with no significant difference in overall remission; the greater fall in regurgitation frequency with the compound is reported without an effect size.

Accelerated Fracture Healing

A non-randomised controlled trial in 100 adults with closed fractures found faster radiological union and less pain when 75 mg twice daily was added to standard orthopaedic care, following animal and drug-repositioning work. Allocation was not random and the study is single-centre and unreplicated.

Magnitude: Mean time to fracture union was about one week shorter than with standard care alone, with significantly better radiological healing scores at four, eight and twelve weeks (p<0.05).

Improved Cardiac Function After Myocardial Infarction

A randomised trial in 50 patients after myocardial infarction — a heart attack — found ejection fraction (the share of blood the heart pumps out per beat) rose over nine months with the compound but not without it. The comparison is within-group rather than between-arm, so the signal is weak.

Magnitude: Median ejection fraction rose from 54% at day three to 62% at nine months with the compound, and from 53% to 59.5% without it; no between-group comparison of the change was reported.

Speculative 🟨

Systemic Antioxidant and Stress-Protein Signalling

Cell and rodent work shows induction of heme oxygenase-1 and Nrf2-driven anti-inflammatory signalling. No human trial has measured a systemic antioxidant outcome, so the basis is mechanistic only.

Neuroprotection in Neurodegenerative Disease

A review of zinc and carnosine biology argues both components buffer the metal dysregulation seen in Alzheimer’s disease, vascular dementia and prion disease. Evidence is in vitro and rodent; no human outcome study exists.

Benefit-Modifying Factors

  • Baseline serum zinc: The single strongest modifier. In the manufacturer’s dose-response analysis, baseline zinc modified the response to 300 mg/day; people starting below 70 µg/dL gained most, while those already replete gained little beyond the local mucosal effect.

  • Carnosinase activity (CNDP1 genotype): Serum carnosinase, encoded by CNDP1, destroys circulating carnosine within minutes. Individuals with high-activity variants clear the dipeptide faster, which is largely irrelevant for the local gut effect but may matter for any systemic carnosine action.

  • Zinc transporter and metallothionein variants: Common polymorphisms in SLC30A8 (a zinc transporter) and the metallothionein genes (metallothionein is the cell’s main zinc-storage protein) alter how efficiently absorbed zinc is buffered, and plausibly shift how much benefit a dose produces.

  • Pre-existing gastrointestinal disease: Benefit is concentrated where mucosa is already injured — active ulcer, gastritis, post-endoscopy ulcer, chemoradiotherapy damage. In an intact, healthy gut lining there is less substrate for the targeting mechanism to act on.

  • Age: Zinc absorption falls and marginal deficiency becomes more common with age, so older adults at the upper end of the target range are more likely to gain from the zinc-repletion effect — but are also closer to the copper-depletion threshold.

  • Sex-based differences: No trial has reported a sex-stratified efficacy analysis for this compound. Women have lower dietary zinc requirements and lower typical intakes; sex-specific effect estimates remain unavailable rather than absent.

  • Concurrent acid suppression: Trials consistently pair the compound with a proton pump inhibitor (a medication that shuts down stomach acid production). Its mucosal-adhesion mechanism depends on an acidic stomach, so heavy acid suppression may alter the local effect.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Dose-Dependent Gastrointestinal Upset

Nausea, abdominal discomfort, constipation and loose stools are the commonest complaints, and they track dose rather than duration — the expected consequence of delivering a metal salt to an already-irritable gut lining. The individual-patient meta-analysis of four placebo-controlled RCTs found all doses from 75 to 300 mg/day tolerable overall, but identified a clear dose-response relationship for gastrointestinal disorders specifically. Reassuringly, when the compound was added to triple antibiotic therapy it produced no excess of total adverse events. Symptoms are mild, reversible on dose reduction, and rarely force discontinuation.

Magnitude: Gastrointestinal adverse drug reactions occurred in 0.0% of patients at 75 mg/day, 2.1% at 150 mg/day and 14.9% at 300 mg/day, against 3.0% on placebo, in the pooled individual-patient analysis.

Medium 🟥 🟥

Copper Depletion on Long-Term Use

Zinc and copper compete for the same intestinal transporter, and sustained zinc intake induces metallothionein in gut cells, which traps copper and excretes it. In a one-year RCT in 75 haemodialysis patients, adverse events requiring dose reduction — copper deficiency among them — occurred in both arms but significantly more often with zinc acetate at 50 mg elemental zinc daily than with polaprezinc at 34 mg. The chelate’s slower systemic zinc delivery is the plausible reason, but it reduces rather than removes the hazard.

Magnitude: Dose-reduction-requiring adverse events including copper deficiency were significantly more frequent with zinc acetate (50 mg zinc/day) than with polaprezinc (34 mg zinc/day) over 52 weeks; per-arm incidence figures were not reported.

Low 🟥

Copper-Deficiency Anaemia, Low Blood Counts and Nerve Damage

A systematic review of 37 published cases links prolonged excess zinc to anaemia and low white-cell counts, often misread as myelodysplastic syndrome (a bone-marrow disorder). Daily elemental zinc ranged from roughly 50 mg upward over weeks to years. Counts recover with copper repletion; nerve damage recovers slowly.

Magnitude: Serum copper was reduced in all 37 cases; anaemia was present in nearly all, at daily elemental zinc doses from approximately 50 mg to more than 1,500 mg.

Hypersensitivity and Hepatic Enzyme Elevation

The Japanese prescribing information lists rash, itching and raised liver enzymes as uncommon reactions, and the pharmacology review of the compound records the same profile. These are post-marketing observations rather than trial findings, and no controlled study has been designed to detect them.

Magnitude: Not quantified in available studies. No controlled trial has been powered for these events, and the underlying data are spontaneous post-marketing reports without denominators.

Unestablished Safety of the Supplement Form

The European Food Safety Authority concluded in 2022 that it could not establish the safety of zinc-L-carnosine as a novel food, because the applicant failed to characterise the fraction of small and nanoscale particles. This is a gap in evidence, not an observed harm.

Magnitude: Not quantified in available studies. The regulator declined to evaluate the toxicology dossier at all once particle characterisation was found inadequate, so no exposure-response figure exists.

Speculative 🟨

Chaperone Inhibition

In vitro, the compound binds heat shock protein 70 and inhibits its chaperone activity — the opposite of the induction seen in gut tissue. No human data exist; the basis is cell work alone.

Immune Blunting at High Zinc Intakes

Sustained high zinc intake is thought to impair immune cell function, partly through copper depletion. No human study has tested this for zinc-L-carnosine specifically; the concern is extrapolated from zinc-salt pharmacology and mechanistic reasoning.

Risk-Modifying Factors

  • Baseline copper and ceruloplasmin: Anyone starting with low-normal copper has less reserve before zinc-driven depletion becomes clinically apparent. Ceruloplasmin (the main copper-carrying protein in blood) falls before symptoms appear.

  • Baseline serum zinc: Those already replete gain little and carry the full copper-displacement risk. The risk-benefit ratio inverts as baseline zinc rises above roughly 80 µg/dL.

  • Chronic kidney disease and dialysis: Kidney patients accumulate zinc and are over-represented in copper-deficiency reports; the haemodialysis trial found copper problems even at 34 mg zinc daily.

  • Bariatric surgery and malabsorption: Altered gut anatomy already predisposes to copper deficiency. Adding a zinc load compounds a pre-existing vulnerability and accelerates the onset of low blood counts.

  • Sex-based differences: No sex-stratified safety analysis exists for this compound. Because women’s tolerable upper zinc intake is set slightly lower, an identical dose represents a proportionally larger exposure.

  • ATP7A and ATP7B variants: These genes encode the copper-export pumps; carriers of reduced-function variants handle a copper squeeze poorly, and patients with Wilson disease (an inherited copper-overload disorder) on zinc therapy are the classic treatment-induced copper-deficiency population.

  • Age: Older adults have reduced marrow reserve and slower nerve repair, so the same degree of copper depletion produces more anaemia and less recoverable neuropathy (nerve damage) at the upper end of the target range.

Key Interactions & Contraindications

  • Tetracycline and quinolone antibiotics (doxycycline, minocycline, ciprofloxacin, levofloxacin): Caution. Zinc chelates these antibiotics and cuts their absorption, risking treatment failure. Separation of at least two hours before or four to six hours after the antibiotic is the usual mitigation.

  • Penicillamine and trientine: Absolute contraindication to unsupervised combination. These copper chelators are used in Wilson disease; adding zinc compounds copper removal and can precipitate deficiency. Only under specialist supervision with copper monitoring.

  • Bisphosphonates (bone-density medications; alendronate, risedronate): Caution. Divalent metals reduce bisphosphonate absorption substantially. The conventional mitigation is a fasting bisphosphonate dose on waking with zinc-L-carnosine delayed by at least two hours.

  • Proton pump inhibitors and H2 blockers (medications that cut stomach acid; omeprazole, esomeprazole, famotidine): Monitor. Acid suppression reduces dietary zinc absorption and alters the acid-dependent dispersal of the complex. Trials deliberately combined them, so co-use is established rather than prohibited.

  • Over-the-counter antacids and non-steroidal anti-inflammatory drugs (calcium carbonate, magnesium hydroxide, ibuprofen, naproxen): Caution with antacids, which bind zinc; separate by two hours. Anti-inflammatory drug co-use is the intended setting, but stomach protection does not protect kidney or heart.

  • Copper supplements: Monitor, and generally desirable. Copper taken with zinc competes for absorption, so several hours of separation is standard; a 1–2 mg daily copper intake offsets depletion during prolonged use.

  • Iron and calcium supplements: Caution. Both compete with zinc for the same divalent-metal transporter, blunting zinc uptake in either direction. Separation of at least two hours, rather than one combined multi-mineral dose, preserves both.

  • Other zinc-containing supplements and lozenges: Caution. Stacking zinc picolinate, gluconate or cold lozenges on top of the compound pushes total elemental zinc past the 40 mg daily upper limit and accelerates copper loss.

Populations who should avoid Zinc-L-carnosine:

  • Anyone with documented copper deficiency, or unexplained anaemia or low white-cell or platelet counts, until copper status is corrected and the cause identified.
  • Wilson disease patients on prescribed chelation, except under hepatology supervision with scheduled copper and ceruloplasmin monitoring.
  • People with a known hypersensitivity reaction to zinc-L-carnosine, zinc salts or carnosine.
  • Pregnant and lactating women: the European Food Safety Authority novel-food assessment explicitly excluded this group, and the applicant proposed use only above age 12.
  • People with advanced chronic kidney disease (estimated glomerular filtration rate, a measure of kidney filtering capacity, below 30 mL/min/1.73 m²) who are not under nephrology supervision, given documented zinc accumulation and copper depletion in dialysis populations.

Risk Mitigation Strategies

  • Total elemental zinc ceiling of 40 mg daily: Zinc from every source counts. At 150 mg/day the compound supplies about 34 mg, leaving almost no headroom — the ceiling prevents the copper depletion behind anaemia and low blood counts.

  • Companion copper intake of 1–2 mg daily on prolonged use: Taken several hours apart from the zinc dose. Directly offsets the transporter competition and metallothionein trapping that drive copper deficiency on courses beyond about three months.

  • Copper and ceruloplasmin measured at baseline and at three to six months: Falling ceruloplasmin precedes anaemia and neuropathy, so this catches depletion while it is still fully reversible with copper repletion and dose reduction.

  • Dosing with food and splitting of the daily dose: Halves the peak luminal zinc concentration, which is what drives the dose-dependent nausea and abdominal discomfort seen across the placebo-controlled trials.

  • Two or more hours of separation from antibiotics and other minerals: Prevents chelation-driven loss of tetracycline and quinolone absorption, and preserves iron and calcium uptake.

  • Opening dose of 75 mg daily with step-up after one to two weeks: A lower opening dose lets gastrointestinal tolerance be established before reaching the 150 mg regimen used in the ulcer and eradication trials.

  • Defined course rather than open-ended intake: Trials ran four to eight weeks for mucosal indications. Time-limiting exposure caps cumulative zinc and removes most of the copper-depletion window.

Therapeutic Protocol

  • Standard Japanese regimen: 75 mg twice daily, morning and evening, totalling 150 mg/day — about 34 mg elemental zinc and 116 mg L-carnosine. This is the licensed anti-ulcer dose and the dose used in most eradication and ulcer-healing trials.

  • Supplement-sector regimen: 37.5 mg twice daily, totalling 75 mg/day and about 17 mg elemental zinc. This is the dose used in the gut-permeability trials and in most PepZin GI products sold outside Japan.

  • Zinc-repletion regimen: 150 mg/day where baseline serum zinc is 70 µg/dL or above, and 300 mg/day where it is below 70 µg/dL, following the manufacturer’s dose-response analysis of its own placebo-controlled trials.

  • Competing approach — rebamipide: 300 mg/day, the standard mucosal protectant in Korean and Japanese practice, matched zinc-L-carnosine for post-endoscopy ulcer healing. Neither is established as the default.

  • Competing approach — acid suppression alone: Proton pump inhibitor monotherapy remains the conventional Western treatment for ulcer healing, and the mucosal-protectant addition is a Japanese and Korean practice rather than a global one.

  • Popularising groups: Hamari Chemicals and Zeria Pharmaceutical developed and popularised the medical regimen in Japan; the PepZin GI trademark, licensed by Hamari Chemicals USA, popularised the 37.5 mg twice-daily supplement regimen in North America.

  • Timing of day: Split morning and evening dosing is standard, with the evening dose commonly taken after the last meal so the compound coats the stomach overnight, when acid exposure is longest and unbuffered.

  • Split versus single dose: Splitting is used in every published trial. It maintains mucosal contact across the day and blunts the peak luminal zinc concentration responsible for dose-dependent nausea.

  • Half-life: The intact complex is not meaningfully absorbed and acts topically with several hours of mucosal residence; carnosine reaching plasma is cleaved within minutes, while absorbed zinc turns over slowly over weeks.

  • Dosing with food: Taken with or just after meals. Food slows gastric emptying and extends mucosal contact while reducing irritation, at some cost to zinc absorption from meals rich in phytate, a mineral-binding compound in wholegrains and legumes.

  • Genetic considerations: No pharmacogenetic dosing rule exists. CNDP1 carnosinase variants alter circulating carnosine half-life, and ATP7A/ATP7B copper-pump variants argue for more conservative dosing and earlier copper monitoring rather than a different dose.

  • Sex-based differences: No trial has reported sex-stratified dosing or response. Because tolerable upper zinc intake is set lower for women, the 300 mg repletion dose warrants proportionally closer monitoring.

  • Age considerations: Older adults absorb zinc less efficiently but clear it more slowly and have less marrow reserve. The 150 mg regimen is usually retained, with copper monitoring brought forward rather than the dose reduced.

  • Baseline biomarkers: Serum zinc determines the repletion dose directly. Baseline copper, ceruloplasmin and a full blood count set how long the course can safely run before reassessment.

  • Pre-existing conditions: Active ulcer, gastritis, post-endoscopy ulcer and chemoradiotherapy mucositis are where trials show benefit. Chronic kidney disease, malabsorption and Wilson disease all call for specialist oversight rather than standard dosing.

Discontinuation & Cycling

  • Course-based, not lifelong: Every controlled trial ran a defined course — one week for colitis enemas, four to eight weeks for ulcer healing and mucositis, up to a year only in dialysis zinc repletion. Indefinite use has not been studied.

  • No withdrawal syndrome: No rebound acid secretion, dependence or discontinuation reaction has been reported, which distinguishes it sharply from proton pump inhibitors, where abrupt withdrawal triggers rebound hypersecretion.

  • No taper required: Because there is no dependence or receptor adaptation, the compound is stopped outright at the end of a course. Tapering is used only where the aim is to test symptom recurrence.

  • Cycling for copper safety, not efficacy: Efficacy does not wane, so cycling is not needed to preserve response. Scheduled breaks are nonetheless sensible to let copper status recover during extended use.

  • A practical cycle: Eight weeks on, four weeks off, with copper and blood count checked during the break, matches trial durations while capping cumulative zinc exposure.

  • Stopping on adverse events: Persistent nausea, unexplained fatigue, falling blood counts or new numbness are reasons to stop immediately and check copper rather than to reduce the dose and continue.

Sourcing and Quality

  • Named, characterised raw material: PepZin GI, the crystalline chelate from Hamari Chemicals, is the form used in most Western trials. Generic “zinc carnosine” may be a physical blend of zinc salt and carnosine rather than a true chelate.

  • Chelate versus blend: The targeting mechanism depends on the crystalline complex. A label listing zinc and L-carnosine as separate ingredients does not deliver the same product, whatever the totals suggest.

  • Declared elemental zinc: Labels vary between stating compound weight and zinc content. 75 mg of the compound supplies roughly 17 mg elemental zinc; this figure, not the compound weight, governs the 40 mg daily ceiling.

  • Third-party testing: NSF International, USP Verified and Informed Choice certifications confirm identity and heavy-metal limits. Zinc raw materials are a recognised route for cadmium and lead contamination.

  • Reputable suppliers: Integrative Therapeutics, Doctor’s Best, Swanson and Seeking Health all market PepZin GI-based products; in Japan the prescription form is Promac from Zeria Pharmaceutical, dispensed through pharmacies.

  • Capsules versus chewables for gut indications: Lozenge and mouthwash formulations were developed for oral mucositis and deliver the compound to the mouth rather than the stomach, so they do not substitute for oral capsules.

  • The European regulatory position: The European Food Safety Authority has not authorised zinc-L-carnosine as a novel food, so products sold into that market may be irregular and are unlikely to have been assessed for particle size.

Practical Considerations

  • Time to effect: Symptom relief in ulcer trials appears within one to two weeks, endoscopic healing is assessed at four to eight weeks, and the gut-permeability effect required 14 days of dosing to reach full size in the exercise trial.

  • Common pitfall — ignoring total zinc: People stack the compound with a multivitamin, a zinc lozenge and a mineral supplement, crossing the 40 mg daily zinc ceiling without noticing and inviting copper depletion.

  • Common pitfall — expecting systemic effects: The compound is designed to act locally on mucosa. Taking it for general antioxidant or longevity purposes rests on cell and animal work with no human outcome data behind it.

  • Common pitfall — treating it as an acid blocker: It is neither an antacid nor an acid suppressant, so it will not relieve reflux quickly. Substituting it for prescribed acid suppression is a recognised error.

  • Regulatory status: A prescription medication in Japan since 1994 and available in parts of Asia; an unapproved dietary supplement in the United States, marketed without disease claims; not authorised as a novel food in the European Union.

  • Cost and accessibility: Inexpensive and widely available online, typically a modest monthly cost at supplement doses. It is not reimbursed outside Japan, which is one reason large Western efficacy trials have never been funded.

Interaction with Foundational Habits

  • Sleep: Indirect and favourable. The compound has no sedative or stimulant action, but by easing nocturnal gastric discomfort and reflux symptoms it can remove a common cause of night-time waking. Evening dosing after the last meal is the conventional timing for this reason, and a registered trial has examined heartburn relief alongside sleep outcomes.

  • Nutrition: Direct and bidirectional. Phytate in legumes, wholegrains and nuts binds zinc and reduces absorption; animal protein enhances it. Taking the dose with or just after a meal extends mucosal contact and reduces nausea. Prolonged use depletes copper, so shellfish, liver, nuts and dark chocolate become worth deliberately including.

  • Exercise: Direct and protective in one setting. In eight athletes, 14 days of dosing cut the exercise-induced rise in intestinal permeability by 70% after core temperature rose 2 °C, suggesting value around heat-stressed endurance work. There is no evidence it aids recovery, hypertrophy or performance, and no reason to time it around resistance training.

  • Stress management: Indirect. Psychological stress raises gastric acid output and impairs mucosal defence, the pathway the compound acts on, and rodent stress-ulcer models are part of its original evidence base. No human study has measured cortisol or any stress marker, so it buffers a consequence of stress rather than altering the stress response.

Monitoring Protocol & Defining Success

Before starting, the useful baseline is a fasting morning serum zinc drawn without haemolysis, together with serum copper, ceruloplasmin and a full blood count with differential. These four define both the reason to take the compound and the ceiling on how long it can safely be taken, because zinc repletion is the intended effect and copper depletion is the principal hazard. Where the indication is mucosal rather than nutritional, alkaline phosphatase and a symptom score matter more than serum zinc itself. Ongoing monitoring is light: repeat serum zinc at four weeks to confirm the dose is working, then check copper, ceruloplasmin and blood count at three months and every six months thereafter for anyone continuing beyond a single defined course. Endoscopic reassessment, where an ulcer was the indication, follows the four-to-eight-week schedule used in the trials.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum zinc 80–120 µg/dL Confirms deficiency and tracks repletion Fasting morning draw; falls with inflammation and with red-cell breakdown in the sample, so pair with C-reactive protein (CRP, a general inflammation marker). Conventional labs flag only below 70 µg/dL
Serum copper 90–130 µg/dL Detects the principal hazard of sustained zinc intake Conventional ranges start near 70 µg/dL; functional practice treats low-normal as an early warning. Best paired with ceruloplasmin
Ceruloplasmin 25–45 mg/dL Falls before anaemia or nerve symptoms appear The more sensitive of the two copper markers. Also rises with inflammation, so interpret alongside CRP
Zinc-to-copper ratio 0.7–1.0 Single best summary of mineral balance on therapy Ratios above 1.2 signal displacement even when both absolute values sit inside reference ranges
Full blood count with differential Haemoglobin and white-cell counts within laboratory reference; no downward trend Copper deficiency presents first as anaemia and a falling white-cell count Bone-marrow appearances are frequently misread as myelodysplastic syndrome, so any zinc use should be flagged to the haematologist
Alkaline phosphatase 70–100 IU/L A zinc-dependent enzyme that falls in functional zinc deficiency Cheap, already on most standard panels. Low values support a zinc deficit that serum zinc may miss
Faecal calprotectin Below 50 µg/g Objective marker of gut mucosal inflammation where the indication is intestinal No established target for this compound specifically; track change from the individual’s own baseline. Single stool sample, no fasting

Qualitative markers worth tracking alongside the laboratory panel:

  • Frequency and intensity of upper-abdominal burning, fullness after meals and night-time discomfort
  • Belching, nausea and abdominal distension, scored weekly rather than recalled
  • Taste acuity, particularly the ability to detect salt and sweetness, where taste disturbance was the reason for starting
  • Appetite and food intake, which is the endpoint that matters most in chemotherapy-related taste disturbance
  • Energy levels and exercise tolerance, which decline early in copper deficiency before blood counts fall
  • Numbness, tingling or gait unsteadiness — the neurological warning signs of copper depletion, and the ones that recover least completely

Emerging Research

  • Infant reflux trial: A two-centre randomised trial (NCT06678997) at Sapienza University of Rome enrolled 60 infants with gastro-oesophageal reflux, completed in 2025 and reported in 2026. It extends the mucosal-protection case into a population where acid suppression is contested.

  • Heartburn and sleep trial: A study of the PepZin GI material (NCT07379645) in 50 adults, sponsored by NutriScience Innovations, completed primary data collection in May 2026. Industry sponsorship of the ingredient supplier is a direct commercial interest in the outcome.

  • Reflux maintenance trial: A phase 4 trial in 80 patients (NCT03467438) at Policlinico San Matteo, Pavia, tested whether the compound maintains remission of reflux disease. Its status remains unknown and no results have been posted, which itself limits what can be concluded.

  • Radiotherapy dysphagia trial: A phase 3 trial in 40 breast cancer patients (NCT03997188) tested prevention of swallowing difficulty during adjuvant radiotherapy — one of the few Western academic trials of the compound.

  • Oncology repurposing: A completed phase 1/2 study in 12 men (NCT05549778) tested it in treatment-resistant prostate cancer, following target identification work on peroxiredoxin 5, an antioxidant enzyme. The sample is far too small to support any clinical claim.

  • Evidence that could weaken the case: The 2026 oral mucosa meta-analysis showed the mucositis effect disappearing under random-effects pooling, and larger trials could confirm that the signal is an artefact of small, non-randomised studies.

  • Regulatory evidence gap: The European Food Safety Authority opinion identified particle characterisation and comparative bioavailability against a conventional zinc source as the unanswered questions. Resolving them would settle whether the chelate offers any absorption advantage.

  • Structural funding bias: No institutional payer reimburses the compound outside Japan, while generic acid suppressants are cheap and covered, so there is no financial incentive for insurers or health systems to fund the large comparative trials that would settle the question.

Conclusion

Zinc-L-carnosine occupies an unusual position: a medication with three decades of routine prescription use in one country and almost no regulatory standing anywhere else. What it does well is mostly narrow and local. It sticks to injured stomach and gut lining and releases zinc there, and the evidence for faster ulcer healing, better results when added to antibiotic treatment for the ulcer-causing bacterium, and reliable correction of low zinc is reasonably firm. The barrier-protection finding in healthy volunteers is the result most likely to interest anyone taking anti-inflammatory medication regularly or training hard in the heat, but it rests on two small studies measuring a laboratory marker rather than how anyone felt.

Beyond that the picture thins quickly. The mouth-ulcer claim weakens as soon as the statistics are handled differently. The liver, bone and heart signals rest on single trials, and the ageing and brain claims rest on cells and rodents alone.

The evidence base carries a visible funding pattern: much of the pivotal work, including the combined analysis behind the low-zinc claim, was produced by the manufacturer, one of the newer trials is funded by the ingredient supplier, and the most accessible consumer overview is published by a company selling the product. No insurer anywhere outside Japan pays for it, which is part of why no large independent trial exists.

The main hazard is straightforward and manageable: sustained zinc intake displaces copper, and the total zinc load, not the brand, is what determines whether that becomes a problem.

Top - Benefits - Risks - Protocol